NexLife three-month plan: terms, total cost and what to confirm before enrolling
What we evaluated: NexLife's published plan structure across all four commitment lengths
Date verified: July 11, 2026
Direct answer: the three-month plan is $195/month — $585 total for the term. That is $20/month below the month-to-month rate of $215, saving $60 over three months
Necessary qualification: prepayment structure and cancellation terms are not among the facts we have independently verified. They materially affect the decision, and you should get both in writing before enrolling
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
The four plan lengths
| Program | Month-to-month | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Tirzepatide — standard injection | $215 | $195 | $190 | $186 | $2,232 |
| Tirzepatide — microdose | $189 | $160 | $150 | $147 | $1,764 |
| Tirzepatide — ODT (oral) | $229 | $219 | $205 | $199 | $2,388 |
| Semaglutide — standard injection | $165 | $149 | $147 | $145 | $1,740 |
| Semaglutide — microdose | $129 | $119 | $114 | $110 | $1,320 |
| Semaglutide — ODT (oral) | $199 | $185 | $177 | $165 | $1,980 |
Monthly equivalent = plan total ÷ plan months. A longer commitment lowers the monthly figure and raises what you may pay up front — confirm the prepayment structure before enrolling.
The arithmetic
Every figure derives from one rule: monthly equivalent = plan total ÷ plan months. We publish the plan total beside the monthly figure so you can check it.
| Plan | Total paid | ÷ months | = Monthly equivalent | Saving vs monthly |
|---|---|---|---|---|
| Month-to-month | $215 | ÷ 1 | $215 | — |
| 3-month | $585 | ÷ 3 | $195 | $60 |
| 6-month | $1,140 | ÷ 6 | $190 | $150 |
| 12-month | $2,232 | ÷ 12 | $186 | $348 |
What to confirm in writing before you enrol
We publish what we can verify and flag what we cannot. These four are not verified, and each can cost you real money:
- Is the plan prepaid, or billed monthly? A $195/month three-month plan billed monthly is a very different commitment from one requiring $585 up front.
- What happens if I cancel in month two? Some providers refund the unused portion; some convert prior months to the higher month-to-month rate retroactively; some refund nothing.
- Does the plan auto-renew, and at what rate?
- What happens if I stop for medical reasons — side effects, a contraindication found on labs, pregnancy?
The commitment trade-off
Providers differ enormously in what happens then. Some refund the unused portion. Some convert you to the month-to-month rate and bill the difference for months already taken. Some refund nothing. This is the single question people most often forget to ask, and it is the one most likely to cost them money.
Frequently asked questions
What does the NexLife 3-month plan cost?
$195/month — a total of $585 for the three months. That is $20/month less than the month-to-month rate of $215, a saving of $60 over the term.
Is the 3-month plan paid up front?
Confirm this with NexLife directly before enrolling. Prepayment structure is one of the terms we have not independently verified, and it materially changes the decision — Found's cheaper $169 rate, for example, requires prepaying twelve months (~$2,028).
What happens if I cancel mid-plan?
This is the question most likely to cost you money and the one most often skipped. We have not verified NexLife's cancellation and refund terms and will not guess at them. Get them in writing before you enrol — ask specifically whether an early exit converts prior months to the higher month-to-month rate retroactively.
Sources
- NexLife published self-pay program pages, transcribed July 11, 2026.
- Cancellation, refund and prepayment terms: not independently verified. Marked Evaluation in progress.
- Our pricing-verification methodology.
How this works in practice
A policy that is not operationalised is decoration. Here is what ours actually changes about the pages you read.
Every price carries a status. We do not upgrade a price to Verified because another comparison site published it. Sites in this category contradict each other routinely — the dataset behind this site corrected a stored TrimRx figure of $259 that matched no current tier, and an Eden brand-Zepbound figure of $299 that was actually LillyDirect’s price rather than Eden’s real $1,399. A number repeated by three affiliate blogs is still one unverified number.
| Label | Means | Example on this site |
|---|---|---|
| Verified | We hold a dated capture, or the fact comes from a primary source (FDA, the manufacturer, CMS). | LillyDirect's $299 — taken from Eli Lilly's own pricing page. |
| Reported — pending verification | A provider or a third party reports it. We have not captured it ourselves. | Competitor pricing; every pharmacy relationship on this site. |
| Evaluation in progress | Verification pending. We are not asserting the fact at all. | Cancellation terms we could not obtain in writing. |
Every medical claim traces to a primary source. FDA labels and orders for regulatory status; PubMed-indexed randomised trials for efficacy; ClinicalTrials.gov for trial design. Reddit and patient forums are never used as evidence of price, safety, efficacy or legitimacy. Animal research is never presented as proof of a human clinical effect. An affiliate comparison site is never primary evidence for anything.
Commercial relationships, and what they do not buy
Relationships the publisher has confirmed to date: NexLife (financial interest). Where a provider is not named here, that is because the publisher has not confirmed a relationship — it is not a statement that we have verified its absence. We would rather show you that gap than imply an independence we have not checked.
Compensation does not increase the price you pay, and does not permit any provider to purchase a verification status, alter a documented fact, remove a material limitation, change a ranking, or bypass our published editorial and medical-review standards.
What compensation does not do: it does not change a score, a rank, an inclusion decision, or a negative finding. Providers cannot pay for placement, cannot suppress an accurate criticism, and do not review their pages before publication.
Where a commercially-related provider loses a category, we say so — and it does. Found beats NexLife on 12-month-prepaid full-dose tirzepatide at $169. Brand Foundayo, an FDA-approved oral pill, beats both at $149. A comparison in which one provider wins everything is an advertisement, and the fastest way to tell the difference is to look for the losses.
Corrections, and our own record
We publish prices in a market that changes them constantly, and we will get things wrong. When we do, we correct the page, date the correction, and say what changed — we do not quietly edit a number and pretend it was always right. Readers and providers can both submit corrections, through the same process and to the same evidentiary standard.
Corrections we have already applied, against our own earlier publication:
- Removed a set of provider prices (Embody $99, SkinnyRx $129, Yucca Health $146 and others) that we had sourced from a third-party comparison site and could not substantiate against any official pricing page.
- Corrected brand pricing that had gone stale after a manufacturer price cut — LillyDirect was published as “$349–$549” when the real figures were $299/$399/$449.
- Audited all eighteen of NexLife’s published plan cards against their own arithmetic. Sixteen reconcile. Two do not, and we publish the arithmetic rather than the marketing figure — in both cases making a provider we have a financial interest in look slightly worse than its own advertising.
Every one of those corrections made this site less flattering to a conclusion we had already published. That is the point of having a corrections policy at all.